Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 26 of 30
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
NCT00857350
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
NCT00673673
Functional MRI of Stress in Obesity
NCT01719484
TEENCOPE: An Internet Coping Skills Training Program for Teens With Type 1 Diabetes
NCT00684658
Pharmacotherapy & CM for Opioid and Cocaine Dependence
NCT00838981
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
NCT00645944
Modification of Cognitive Processing Therapy (CPT-C) for PTSD and Alcohol Dependence
NCT00639288
Ziprasidone in the Psychosis Prodrome
NCT00635700
Cannabinoids, Neural Synchrony, and Information Processing
NCT00708994
Naltrexone for Heavy Drinking in Young Adults
NCT00568958
Compromised Microcirculation in Women With Polycystic Ovary Syndrome
NCT00757185
Rapamycin for Prevention of Chronic Graft-Versus-Host Disease
NCT00623012
Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects
NCT00700076
Basic Research Study to Examine the Relation Between Muscle Insulin Resistance and Lipid Production in the Liver.
NCT02196051
Positive Lifestyles Using Safety
NCT00836290
The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse
NCT00773422
Women With Cancer: An Exercise Study to Promote Health
NCT01102985
Stress Reduction to Reduce Risk for Arrhythmia in ICD Patients (The RISTA Study)
NCT00627263
Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches
NCT00660192
Memantine Treatment Study of Pathological Gambling
NCT00585169
Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism
NCT02675530
Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse
NCT00809835
Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder
NCT00536198
Computer-Based Training in Cognitive Behavior Therapy
NCT00350610
The Role of Stress in Self-Control, Coping, and Emotion Regulation
NCT01554501
Cortical GABA Concentrations in Insomnia
NCT00765752
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
NCT00612274
Racial Differences in Orthostatic Tolerance
NCT00844181
Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Original Study
NCT00567281
Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues
NCT00585520
Cocaine Withdrawal and Pharmacotherapy Response
NCT00566969
Examining Heart Attacks in Young Women
NCT00597922
Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia
NCT00539123
Treatment of Binge Eating in Obese Patients in Primary Care
NCT00537810
Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China
NCT00757744
N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
NCT00539188
Ceftriaxone in the Management of Bipolar Depression
NCT00566111
Pharmacogenetics of Cannabinoid Response
NCT00678730
Cannabinoid Receptor Function & Alcoholism
NCT00624715
Message Framing for Telephone Quitline Callers
NCT00589277
Varenicline and Nicotine Interactions in Humans (VA)
NCT00606892
Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
NCT00516919
GABA (Gamma Amino Butyric Acid) Medication for Tobacco
NCT00644137
Early Versus Delayed Routine HIV Testing in Connecticut Jails
NCT00624247
Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence
NCT00563797
An Integrated Substance Abuse-Domestic Violence (SADV) Treatment Outcome Study
NCT07140276
Daily Exposure Monitoring to Prevent Hearing Loss
NCT01714375
Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome
NCT00529308
Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers
NCT00502216
Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients
NCT00577005
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.